Adipose tissue; Dysosmobacter welbionis J115T; Glucose tolerance; Gut microbiota; Metformin; Obesity; Prebiotics; Type 2 diabetes; Humans; Animals; Mice; Obesity/drug therapy; Diet, High-Fat; Metformin/therapeutic use; Metformin/pharmacology; Diabetes Mellitus, Type 2/drug therapy; Clostridiales; Diabetes Mellitus, Type 2; Dysosmobacter welbionis; Internal Medicine; Endocrinology, Diabetes and Metabolism
Abstract :
[en] [en] AIMS/HYPOTHESIS: We aimed to investigate the association between the abundance of Dysosmobacter welbionis, a commensal gut bacterium, and metabolic health in human participants with obesity and diabetes, and the influence of metformin treatment and prebiotic intervention.
METHODS: Metabolic variables were assessed and faecal samples were collected from 106 participants in a randomised controlled intervention with a prebiotic stratified by metformin treatment (Food4Gut trial). The abundance of D. welbionis was measured by quantitative PCR and correlated with metabolic markers. The in vitro effect of metformin on D. welbionis growth was evaluated and an in vivo study was performed in mice to investigate the effects of metformin and D. welbionis J115T supplementation, either alone or in combination, on metabolic variables.
RESULTS: D. welbionis abundance was unaffected by prebiotic treatment but was significantly higher in metformin-treated participants. Responders to prebiotic treatment had higher baseline D. welbionis levels than non-responders. D. welbionis was negatively correlated with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and fasting blood glucose levels in humans with obesity and type 2 diabetes. In vitro, metformin had no direct effect on D. welbionis growth. In mice, D. welbionis J115T treatment reduced body weight gain and liver weight, and improved glucose tolerance to a better level than metformin, but did not have synergistic effects with metformin.
CONCLUSIONS/INTERPRETATION: D. welbionis abundance is influenced by metformin treatment and associated with prebiotic response, liver health and glucose metabolism in humans with obesity and diabetes. This study suggests that D. welbionis may play a role in metabolic health and warrants further investigation.
CLINICAL TRIAL: NCT03852069.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Moens de Hase, Emilie; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium ; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium
Neyrinck, Audrey M ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Rodriguez, Julie ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Cnop, Miriam ; ULB Center for Diabetes Research, Université Libre de Bruxelles, and Division of Endocrinology, Erasmus Hospital, Brussels, Belgium
Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladies métaboliques
Thissen, Jean-Paul ; Pole of Endocrinology, Diabetes and Nutrition, Institute of Experimental and Clinical Research (IREC), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Xu, Yining; Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Beloqui, Ana ; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium ; Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Bindels, Laure B ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium ; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium
Delzenne, Nathalie M ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium
Van Hul, Matthias ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium. Matthias.vanhul@uclouvain.be ; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium. Matthias.vanhul@uclouvain.be
Cani, Patrice D ; Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium. patrice.cani@uclouvain.be ; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium. patrice.cani@uclouvain.be ; Institute of Experimental and Clinical Research (IREC), UCLouvain (Université catholique de Louvain), Brussels, Belgium. patrice.cani@uclouvain.be
Language :
English
Title :
Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention.
Publication date :
February 2024
Journal title :
Diabetologia
ISSN :
0012-186X
eISSN :
1432-0428
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
SPW - Service Public de Wallonie La Caixa Foundation F.R.S.-FNRS - Fonds de la Recherche Scientifique
Funding text :
Food4Gut was supported by the competitive cluster Wagralim from Wallonia (Food4Gut 518 project, convention 1318148). NMD is a recipient of grants from the Fonds de la Recherche Scientifique (FRS-FNRS, convention PINT-MULTI R.8013.19 [NEURON, call 2019] and convention PDR T.0068.19). PDC is a recipient of grants from the FNRS (Projet de Recherche PDR-convention: FNRS T.0030.21, CDR-convention: J.0027.22, FRFS-WELBIO: WELBIO-CR-2022A-02, EOS: program no. 40007505), ARC (Action de recherche concertée: ARC19/24-096) and La Caixa (NeuroGut). The study funders were not involved in the design of the study; the collection, analysis and interpretation of data; or writing of the report; and did not impose any restrictions regarding the publication of the report. Action de Recherche Concertée
International Diabetes Federation (2021) IDF Diabetes Atlas, 10th edn. International Diabetes Federation, Brussels
de Vos WM, Tilg H, Van Hul M, Cani PD (2022) Gut microbiome and health: mechanistic insights. Gut 71:1020–1032. 10.1136/gutjnl-2021-326789 DOI: 10.1136/gutjnl-2021-326789
Van Hul M, Cani PD (2023) The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol 19:258–271. 10.1038/s41574-022-00794-0 DOI: 10.1038/s41574-022-00794-0
Cani PD (2017) Gut microbiota - at the intersection of everything? Nat Rev Gastroenterol Hepatol 14:321–322. 10.1038/nrgastro.2017.54 DOI: 10.1038/nrgastro.2017.54
Van Hul M, Le Roy T, Prifti E et al (2020) From correlation to causality: the case of Subdoligranulum. Gut microbes 12:1–13. 10.1080/19490976.2020.1849998 DOI: 10.1080/19490976.2020.1849998
Cani PD, Depommier C, Derrien M, Everard A, de Vos WM (2022) Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol 19:625–637. 10.1038/s41575-022-00631-9 DOI: 10.1038/s41575-022-00631-9
Everard A, Lazarevic V, Derrien M et al (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60:2775–2786. 10.2337/db11-0227 DOI: 10.2337/db11-0227
Everard A, Lazarevic V, Gaïa N et al (2014) Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. I S M E J Multidiscip J Microb Ecol 8:2116–2130. 10.1038/ismej.2014.45 DOI: 10.1038/ismej.2014.45
Ojo O, Wang X, Ojo OO et al (2022) The effect of prebiotics and oral anti-diabetic agents on gut microbiome in patients with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Nutrients 14:5139. 10.3390/nu14235139 DOI: 10.3390/nu14235139
Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. 10.1038/nature11450 DOI: 10.1038/nature11450
Zhang Q, Hu N (2020) Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 13:5003–5014. 10.2147/DMSO.S286430 DOI: 10.2147/DMSO.S286430
Rosario D, Benfeitas R, Bidkhori G et al (2018) Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling. Front Physiol 9:775. 10.3389/fphys.2018.00775 DOI: 10.3389/fphys.2018.00775
Rodriguez J, Hiel S, Delzenne NM (2018) Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care 21:294–301. 10.1097/MCO.0000000000000468 DOI: 10.1097/MCO.0000000000000468
Rodriguez J, Hiel S, Neyrinck AM et al (2020) Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients. Gut 9:1975–1987. 10.1136/gutjnl-2019-319726 DOI: 10.1136/gutjnl-2019-319726
Neyrinck AM, Rodriguez J, Zhang Z et al (2021) Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial. Eur J Nutr 60:3159–3170. 10.1007/s00394-021-02484-5 DOI: 10.1007/s00394-021-02484-5
Hiel S, Gianfrancesco MA, Rodriguez J et al (2020) Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial. Clin Nutr (Edinburgh, Scotland) 39:3618–3628. 10.1016/j.clnu.2020.04.005 DOI: 10.1016/j.clnu.2020.04.005
Cani PD, Neyrinck AM, Fava F et al (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374–2383. 10.1007/s00125-007-0791-0 DOI: 10.1007/s00125-007-0791-0
Le Roy T, Van der Smissen P, Paquot A et al (2020) Dysosmobacter welbionis gen. nov., sp. nov., isolated from human faeces and emended description of the genus Oscillibacter. Int J Syst Evol Microbiol 70:4851–4858. 10.1099/ijsem.0.003547 DOI: 10.1099/ijsem.0.003547
Le Roy T, Moens de Hase E, Van Hul M et al (2022) Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice. Gut 71:534–543. 10.1136/gutjnl-2020-323778 DOI: 10.1136/gutjnl-2020-323778
Zhou Q, Zhang Y, Wang X et al (2020) Gut bacteria Akkermansia is associated with reduced risk of obesity: evidence from the American Gut Project. Nutr Metab (Lond) 17:90. 10.1186/s12986-020-00516-1 DOI: 10.1186/s12986-020-00516-1
Wu H, Esteve E, Tremaroli V et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858. 10.1038/nm.4345 DOI: 10.1038/nm.4345
Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB (2016) Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front Endocrinol (Lausanne) 7:30. 10.3389/fendo.2016.00030 DOI: 10.3389/fendo.2016.00030
Laurencikiene J, Skurk T, Kulyte A et al (2011) Regulation of lipolysis in small and large fat cells of the same subject. J Clin Endocrinol Metab 96:E2045-2049. 10.1210/jc.2011-1702 DOI: 10.1210/jc.2011-1702
Cani PD, Knauf C (2021) A newly identified protein from Akkermansia muciniphila stimulates GLP-1 secretion. Cell Metab 33:1073–1075. 10.1016/j.cmet.2021.05.004 DOI: 10.1016/j.cmet.2021.05.004
Qian K, Chen S, Wang J, Sheng K, Wang Y, Zhang M (2022) A β-N-acetylhexosaminidase Amuc_2109 from Akkermansia muciniphila protects against dextran sulfate sodium-induced colitis in mice by enhancing intestinal barrier and modulating gut microbiota. Food Funct 13:2216–2227. 10.1039/D1FO04094D DOI: 10.1039/D1FO04094D
Lenoir M, Martin R, Torres-Maravilla E et al (2020) Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes 12:1–16. 10.1080/19490976.2020.1826748 DOI: 10.1080/19490976.2020.1826748
Shin NR, Lee JC, Lee HY et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735. 10.1136/gutjnl-2012-303839 DOI: 10.1136/gutjnl-2012-303839
de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V et al (2017) Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40:54–62. 10.2337/dc16-1324 DOI: 10.2337/dc16-1324
Rodriguez J, Neyrinck AM, Van Kerckhoven M et al (2022) Physical activity enhances the improvement of body mass index and metabolism by inulin: a multicenter randomized placebo-controlled trial performed in obese individuals. BMC Med 20:110. 10.1186/s12916-022-02299-z DOI: 10.1186/s12916-022-02299-z
